BioMedNewsBreaks

WednesdayJun 10, 2026 9:30 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Highlights Fiscal 2026 Growth and Cash Flow Progress in Shareholder Letter

Earth Science Tech (OTC: ETST) provided a business update in a letter to shareholders, highlighting what management described as a transformational fiscal year ended March 31, 2026. The company cited progress across multiple holdings, including the expansion of Mister Meds, turnarounds at DOConsultation and Villas Health, the relaunch of MyOnlineConsultation as a cash flow-positive prescriber network and revenue growth at Peaks that surpassed $2 million during the first week of the fourth quarter. Earth Science Tech said it completed these initiatives without adding debt to its balance sheet, while also repurchasing and retiring more than 3.7 million shares during the…

Continue Reading

WednesdayJun 10, 2026 9:10 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) Advances ONC010 Manufacturing Process Development

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. The work represents a key milestone in the company's chemistry, manufacturing and controls strategy as it advances toward IND-enabling studies and planning for first-in-human clinical evaluation. Onco said the program will focus on optimizing synthetic processes, improving yield and reproducibility and scaling production of key intermediates required for downstream manufacturing and formulation. The…

Continue Reading

TuesdayJun 09, 2026 9:40 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Delivers First Edge AI Intoxication Detection Kiosk Prototypes

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio’s Edge AI Kiosks Use Voice and AI to detect intoxication and fatigue. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced the completion and delivery of its first prototype Edge AI Intoxication Detection Kiosks, a hardware and software platform designed to detect intoxication and fatigue through AI-powered voice analysis. The kiosks are intended for workplace environments and are being developed to help improve safety across industries where drug, alcohol and fatigue monitoring are critical. The company said the prototypes will now undergo testing,…

Continue Reading

MondayJun 08, 2026 1:15 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Oversubscribed $22.5 Million Financing and Growth Strategy in Investor Presentation

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in a virtual investor segment featuring Chief Financial Officer Steve O'Loughlin, who discussed the company's recently completed oversubscribed $22.5 million financing. The presentation focused on the factors supporting the successful capital raise following CNS Pharmaceuticals' strategic reset and acquisition-focused transformation. Management also addressed investor reception to the company's evolving strategy, the participation of healthcare-focused institutional investors and how the strengthened balance sheet positions CNS Pharmaceuticals to pursue potential transformational opportunities. The discussion highlighted the company's long-term growth strategy and efforts to create shareholder value as it advances its next phase of development. To…

Continue Reading

MondayJun 08, 2026 12:00 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances European Commercial Launch Plans for GelrinC

Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company's cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe. The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as…

Continue Reading

MondayJun 08, 2026 11:45 am

BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Advances Ibogaine Drug Development Program 

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.  Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced progress on its Ibogaine Initiative, securing naturally derived ibogaine from two sources in both hydrochloride and freebase forms. The company expects development of finished ibogaine drug products to begin this summer at its GMP-certified manufacturing facility in British Columbia, with plans to produce standardized 50 mg and 100 mg encapsulated dosage formats for research and regulated access programs. The update comes amid growing interest in ibogaine research and expanding public funding for psychedelic therapies, including a recently announced $50 million program in Texas. Optimi said its development program…

Continue Reading

MondayJun 08, 2026 11:35 am

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF)(Frankfurt: W1H) (WKN: A3EKSZ) Signs LOI to Advance ONC010 Development, Appoints VP of Corporate Finance 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced it has entered into a non-binding letter of intent with Nanosoft Polymers as an initial step toward negotiating a services agreement supporting development of its exclusively licensed PNKP inhibitor technology, ONC010. The proposed collaboration would focus on polymer process development, analytical characterization, formulation optimization and manufacturing planning activities designed to support future clinical and regulatory development of the oncology candidate.  The company also appointed Dave Antony as vice president of corporate finance. Antony brings more than 35 years of experience in financial planning, reporting, corporate governance and public company advisory services, including leadership roles…

Continue Reading

MondayJun 08, 2026 9:20 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Showcase AI Drug Discovery Platform at Qdrant Vector Space Day 2026

Oncotelic Therapeutics (OTCQB: OTLC) announced that its proprietary PDAOAI(TM) drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026 in San Francisco on June 11. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development. The presentation will highlight several innovations underpinning the platform, including a proprietary "manifold folding" technique designed to improve semantic…

Continue Reading

FridayJun 05, 2026 10:31 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on Advanced Cancer Drug Delivery 

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a NetworkNewsAudio Audio Press Release examining the growing focus on advanced drug-delivery technologies in oncology. The editorial highlights ongoing challenges in cancer treatment, including drug penetration, tumor targeting, therapeutic resistance and achieving consistent exposure within tumor tissues, factors that continue to drive interest in nanoparticle-based and targeted delivery approaches. The article notes that Oncotelic is advancing its Sapu003 program and Deciparticle platform as part of an effort to improve the delivery and performance of existing cancer therapies. By focusing on nanotechnology-enabled delivery systems and pharmacokinetic optimization, the company is pursuing an approach that aligns with broader industry efforts to enhance therapeutic…

Continue Reading

ThursdayJun 04, 2026 12:55 pm

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Launches Intox AI(TM) for Validation and Testing

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced the launch of its Intox AI(TM) software platform for validation and testing. The AI-driven voice analytics solution is designed to detect intoxication and fatigue by analyzing speech patterns and is capable of identifying indicators associated with cocaine, cannabis, alcohol, psychedelics, narcotics and human fatigue. The company said the technology is intended for deployment through Edge AI kiosks currently nearing prototype manufacturing completion. MindBio Therapeutics Corp. (CSE: MBIO) (Frankfurt: WF6) (OTCQB: MBQIF) is targeting commercialization opportunities…

Continue Reading